1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study

Kyung-Woo Lee, Y-K. Kang, Yee Chao et al.|Annals of Oncology|2023

Cited by 8